MedTrace Logo

Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

NCT06635408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2025-04-24

No results posted yet for this study

Summary

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is:

\- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?

Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Conditions

Interventions

DIAGNOSTIC_TEST

cystatin c

a biomarker to assess renal function

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed A El Erian, Professor · Alexandria University

  • Ashraf A Abdelhalim, Professor · Alexandria University

  • Sherif M El Hadi, Professor · Alexandria University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2025-01-01
Completion
2025-01-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06635408 on ClinicalTrials.gov